Evidence map›Paper›PMID 29094083›Full record

ArticleJournal of global oncology2017

Neoadjuvant Chemotherapy With Capecitabine Plus Cisplatin in Patients With Locally Advanced Nasopharyngeal Cancer: Case Series Study.

Reyad Dada, Mohamed El Sayed, Jamal Zekri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Reyad Dada, , and , King Faisal Specialist Hospital and Research Center, Jeddah; and , Al-Faisal University, Riyadh, Kingdom of Saudi Arabia; and , Cairo University, Cairo, Egypt.
Mohamed El Sayed, , and , King Faisal Specialist Hospital and Research Center, Jeddah; and , Al-Faisal University, Riyadh, Kingdom of Saudi Arabia; and , Cairo University, Cairo, Egypt.
Jamal Zekri, , and , King Faisal Specialist Hospital and Research Center, Jeddah; and , Al-Faisal University, Riyadh, Kingdom of Saudi Arabia; and , Cairo University, Cairo, Egypt.
Alfaisal University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCapecitabine, an oral fluorouracil (5-FU) derivative, has replaced 5-FU in many chemotherapy regimens used in various GI tract cancers. The experience with capecitabine in nasopharyngeal carcinoma (NPC) is limited. PATIENTS AND

methodsWe report on eight patients with locally advanced NPC treated with neoadjuvant chemotherapy with capecitabine and cisplatin.

resultsAll eight patients responded well to the chemotherapy combination and achieved complete remission after definitive chemoradiotherapy. No grade 3/4 toxicities were observed. Five patients experienced a relapse after 6, 8, 9, 12, and 17 months.

conclusionIn the patients studied, capecitabine (in combination with cisplatin) was a safe and effective substitution for 5-FU for the neoadjuvant treatment of locally advanced NPC. Larger prospective clinical studies are required to confirm these results.

Identifiers

PMID29094083
PMCPMC5646894
OpenAlexW2553284143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.